JP2002500638A - ワクチンアジュバントとしての神経成長因子 - Google Patents
ワクチンアジュバントとしての神経成長因子Info
- Publication number
- JP2002500638A JP2002500638A JP54734598A JP54734598A JP2002500638A JP 2002500638 A JP2002500638 A JP 2002500638A JP 54734598 A JP54734598 A JP 54734598A JP 54734598 A JP54734598 A JP 54734598A JP 2002500638 A JP2002500638 A JP 2002500638A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- ngf
- cells
- animal
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.A)動物に、未知の病原体に対する抗体の産生を引き起こさせる能力を有す る、免疫応答誘因ワクチン;及び B)前記ワクチンに対する応答としての、動物による抗体の産生を強化する 、ワクチン効果強化用量の神経成長因子(NGF);を含み、 C)前記動物は免疫不全であり、前記ワクチン及びNGFは、別々にまたは 同時に投与することができる、 ことを特徴とする免疫不全動物のワクチン効果を高める薬剤学的配合物。 2.前記の動物とはヒトであり、前記のワクチンとは、インフルエンザワクチン 、ヘモフィルスインフルエンザワクチン、A型、B型、C型肝炎ウイルスワクチ ン、結核ワクチン、帯状ヘルペスウイルスワクヒン、サイトメガロウイルスワク チン、肺炎球菌肺炎ワクチン、髄膜炎菌髄膜炎ワクチン、ジフテリアワクチン、 破傷風ワクチン、狂犬病ワクチン、ヘリコバクターピロリワクチン、ポリオワク チン、及び痘瘡ワクチンである、請求の範囲第1項に記載の薬剤学的配合物。 3.前記ワクチンの量が約1×10-9gから約1×10-3gであり、NGFの量 は約0.001−100mg/kgである、請求の範囲第1項に記載の薬剤学的配合物。 4.前記ワクチンの量が約1×10-8gから約1×10-4gであり、NGFの量 は約0.1-10mg/kgである、請求の範囲の範囲第1項に記載の薬剤学的配合物。 5.前記NGFの量が約0.3−3mg/kgである、請求の範囲第1項に記載の薬剤学 的配合物。 6.前記のワクチン及びNGFを含有する混合物から成る、請求の範囲第1項に 記載の薬剤学的配合物。 7.前記混合物が、薬剤学的に適当な担体を含有する、請求の範囲第6項に記載 の薬剤学的配合物。 8.A)動物に、未知の病原体に対する抗体の産生を引き起こさせる能力を有す る、免疫応答誘因ワクチン;及び B)前記ワクチンに対する応答としての、動物による抗体の産生を強化する 、ワクチン効果強化用量の神経成長因子(NGF);を含み、 C)前記動物は免疫不全であり、前記ワクチン及びNGFは、別々にまたは 同時に投与することができ、また動物体内ではワクチン効果はNGFによって高 められる、 という薬剤学的配合物を、免疫不全の動物に、ワクチン効果を高めるために投 与することを特徴とするワクチン投与方法。 9.前記動物とはヒトであり、前記ワクチンとは、インフルエンザワクチン、ヘ モフィルスインフルエンザワクチン、A型、B型、C型肝炎ウイルスワクチン、 結核ワクチン、帯状ヘルペスウイルスワクヒン、サイトメガロウイルスワクチン 、肺炎球菌肺炎ワクチン、髄膜炎菌髄膜炎ワクチン、ジフテリアワクチン、破傷 風ワクチン、狂犬病ワクチン、ヘリコバクターピロリワクチン、ポリオワクチン 、及び痘瘡ワクチンである、請求の範囲第8項に記載の方法。 10.前記ワクチンの量が約1×10-9gから約1×10-3gであり、NGF の量は約0.001−100mg/kgである、請求の範囲第8項に記載の方法。 11.前記ワクチンの量が約1×10-8gから約1×10-4gであり、NGFの 量は約0.1−10mg/kgである、請求の範囲第8項に記載の方法。 12.前記NGFの量が約0.3−3mg/kgである、請求の範囲第8項に記載の方法 。 13.前記のワクチンをブースターワクチンとして投与する、請求の範囲第8項 に記載の方法。 14.前記のNGFをブースターワクチン投与の約3−4日前に投与する、請求 の範囲第13項に記載の方法。 15.前記のNGFをワクチンの投与と基本的に同時に投与する、請求の範囲第 13項に記載の方法。 16.前記ワクチンとNGFを注射によって投与する、請求の範囲第8項に記載 の方法。 17.−免疫不全の動物に、未知の病原体に対する抗体の産生を引き起こさせる 能力を有する、免疫応答誘因ワクチンの1回目の用量を投与し; −この1回目の投与後、約1週間から2ヶ月の期間内に、同動物に1)ワ クチンに対する応答としての抗体の産生を強化する、ワクチン効果強化用量の神 経成長因子(NGF)を投与するか、2)ワクチン効果を高めるために、ブース ター用量のワクチンを、ワクチン効果強化用量の神経成長因子(NGF )とともに投与する、 ことを特徴とするワクチン投与方法。 18.前記期間が約10−45日間である、請求の範囲第17項に記載の方法。 19.前記期間が約10−30日間である、請求の範囲第17項に記載の方法。 20.前記期間が約10−20日間である、請求の範囲第17項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84722897A | 1997-05-01 | 1997-05-01 | |
US08/847,228 | 1997-05-01 | ||
PCT/US1998/008652 WO1998048832A1 (en) | 1997-05-01 | 1998-04-30 | Nerve growth factor as a vaccine adjuvant |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002500638A true JP2002500638A (ja) | 2002-01-08 |
JP4205172B2 JP4205172B2 (ja) | 2009-01-07 |
Family
ID=25300123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54734598A Expired - Fee Related JP4205172B2 (ja) | 1997-05-01 | 1998-04-30 | ワクチンアジュバントとしての神経成長因子 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6572866B1 (ja) |
EP (1) | EP0994721B1 (ja) |
JP (1) | JP4205172B2 (ja) |
CN (1) | CN1128637C (ja) |
AT (1) | ATE346606T1 (ja) |
AU (1) | AU727652B2 (ja) |
CA (1) | CA2289040A1 (ja) |
CY (1) | CY1107571T1 (ja) |
DE (1) | DE69836543T2 (ja) |
DK (1) | DK0994721T3 (ja) |
ES (1) | ES2278411T3 (ja) |
NO (1) | NO326022B1 (ja) |
PT (1) | PT994721E (ja) |
WO (1) | WO1998048832A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507537A (ja) * | 2004-07-23 | 2008-03-13 | アドバイシーズ,インコーポレイテッド | 予防接種レスポンスを増強する成長ホルモン放出ホルモン |
JP2017525751A (ja) * | 2014-05-28 | 2017-09-07 | テクニスチェ ユニベルシタト ドレスデン | 免疫療法のための医薬の組合わせ |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011203139B2 (en) * | 1998-02-27 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
DE10012370A1 (de) * | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
PL1648502T3 (pl) * | 2003-07-11 | 2011-05-31 | Intercell Ag | Szczepionki przeciwko HCV |
WO2005122739A2 (en) | 2004-06-15 | 2005-12-29 | The New York Blood Center, Inc. | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
WO2006116053A1 (en) * | 2005-04-22 | 2006-11-02 | Sciclone Pharmaceuticals, Inc. | Immunomodulator compounds as vaccine enhancers |
US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
EP3058954B1 (en) | 2007-08-27 | 2017-03-01 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
EP2535428B1 (en) | 2007-10-01 | 2015-09-09 | Longhorn Vaccines and Diagnostics, LLC | Biological specimen collection and transport system and methods of use |
US8321012B2 (en) | 2009-12-22 | 2012-11-27 | The Invention Science Fund I, Llc | Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject |
CN104203272A (zh) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | 复合抗原序列及疫苗 |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277828B1 (en) * | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
AUPM543894A0 (en) * | 1994-05-04 | 1994-05-26 | Commonwealth Scientific And Industrial Research Organisation | An adjuvant |
-
1998
- 1998-04-30 EP EP98919999A patent/EP0994721B1/en not_active Expired - Lifetime
- 1998-04-30 ES ES98919999T patent/ES2278411T3/es not_active Expired - Lifetime
- 1998-04-30 US US09/269,883 patent/US6572866B1/en not_active Expired - Fee Related
- 1998-04-30 WO PCT/US1998/008652 patent/WO1998048832A1/en active IP Right Grant
- 1998-04-30 AT AT98919999T patent/ATE346606T1/de active
- 1998-04-30 AU AU72664/98A patent/AU727652B2/en not_active Ceased
- 1998-04-30 CA CA002289040A patent/CA2289040A1/en not_active Abandoned
- 1998-04-30 JP JP54734598A patent/JP4205172B2/ja not_active Expired - Fee Related
- 1998-04-30 CN CN98806220A patent/CN1128637C/zh not_active Expired - Fee Related
- 1998-04-30 PT PT98919999T patent/PT994721E/pt unknown
- 1998-04-30 DE DE69836543T patent/DE69836543T2/de not_active Expired - Lifetime
- 1998-04-30 DK DK98919999T patent/DK0994721T3/da active
-
1999
- 1999-10-26 NO NO19995236A patent/NO326022B1/no not_active IP Right Cessation
-
2007
- 2007-02-28 CY CY20071100279T patent/CY1107571T1/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507537A (ja) * | 2004-07-23 | 2008-03-13 | アドバイシーズ,インコーポレイテッド | 予防接種レスポンスを増強する成長ホルモン放出ホルモン |
JP2017525751A (ja) * | 2014-05-28 | 2017-09-07 | テクニスチェ ユニベルシタト ドレスデン | 免疫療法のための医薬の組合わせ |
Also Published As
Publication number | Publication date |
---|---|
NO995236D0 (no) | 1999-10-26 |
WO1998048832A1 (en) | 1998-11-05 |
ES2278411T3 (es) | 2007-08-01 |
CA2289040A1 (en) | 1998-11-05 |
DE69836543T2 (de) | 2007-09-20 |
AU727652B2 (en) | 2000-12-21 |
DK0994721T3 (da) | 2007-04-02 |
EP0994721A4 (en) | 2003-08-27 |
NO995236L (no) | 1999-12-10 |
PT994721E (pt) | 2007-03-30 |
CY1107571T1 (el) | 2013-03-13 |
CN1128637C (zh) | 2003-11-26 |
CN1260722A (zh) | 2000-07-19 |
JP4205172B2 (ja) | 2009-01-07 |
ATE346606T1 (de) | 2006-12-15 |
DE69836543D1 (de) | 2007-01-11 |
AU7266498A (en) | 1998-11-24 |
US6572866B1 (en) | 2003-06-03 |
NO326022B1 (no) | 2008-09-01 |
EP0994721B1 (en) | 2006-11-29 |
EP0994721A1 (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002500638A (ja) | ワクチンアジュバントとしての神経成長因子 | |
Zhang et al. | RGMa mediates reactive astrogliosis and glial scar formation through TGFβ1/Smad2/3 signaling after stroke | |
Tchelingerian et al. | Localization of TNFα and IL-1a immunoreactivities in striatal neurons after surgical injury to the hippocampus | |
DE69931377T2 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
CN110382530A (zh) | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 | |
Lei et al. | Growth factors outside the PDGF family drive experimental PVR | |
JPH08511236A (ja) | 生物学的に活性な因子の毒性を低減させる組成物および方法 | |
Xu et al. | Combined NgR vaccination and neural stem cell transplantation promote functional recovery after spinal cord injury in adult rats | |
US10752675B2 (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein | |
EA029400B1 (ru) | Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения | |
JPH11505516A (ja) | 抗体クラススイッチを刺激する組成物及び方法 | |
US20240199755A1 (en) | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone | |
JP5802553B2 (ja) | ペプチジルジアシルグリセリド | |
JP7096558B2 (ja) | 疼痛治療 | |
Maroldt et al. | Immunohistochemical expression of two members of the GDNF family of growth factors and their receptors in the olfactory system | |
US20220040253A1 (en) | Agonists of Human Kisspeptin Receptor for Modulating Sexual Desire | |
Miotke | Injury-and development-related changes in ciliary neurotrophic factor receptor alpha in the mouse retina and optic nerve | |
US20070082865A1 (en) | Compositions and methods for treatment of airway hypersecretion | |
KR20200049249A (ko) | 만성 뇌졸중 재활 보조제 조성물 | |
JP2016520060A (ja) | invivoでの抗体産生および液性免疫のFGF調節 | |
MX2008007149A (en) | Therapeutic vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080701 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080930 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081016 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111024 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121024 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |